CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Dapagliflozin +2 moredrug
Likely dose
Glipizide 5 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02911792
NCT02911792Phase 4Completed
CompareCT.gov

Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

The University of Texas Health Science Center at San Antonio·interventional·Posted Sep 22, 2016·Updated Nov 30, 2023

In Brief

A Phase 4 clinical trial evaluating Dapagliflozin, Metformin, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 72 participants across 2 sites.

Detailed Summary

The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or without microalbuminuria with dapagliflozin or metformin for 4 months. The metformin-treated group will serve as controls for improved glycemic control, since the investigators have shown that insulin therapy to normalize A1c reduces hyperfiltration and kidney size in T1DM patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 22, 2016
Enrollment StartDec 20, 2016
Primary CompletionJul 11, 2023
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 9.8 years ago

Interventions

Dapagliflozindrug

SGLT2 inhibitor

Metformindrug

Oral diabetes medicine that helps control blood sugar levels.

Glipizide 5 MGdrug

Oral diabetes medicine that helps control blood sugar levels.